Delving into the Latest Updates on Wuhan Renfulikang Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Other Diseases

Respiratory Diseases

Small molecule drug

Degradable Molecular Glue

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1
Degradable Molecular Glue	1

Top 5 Target	Count

RBM39(RNA binding motif protein 39)	1
autotaxin(Ectonucleotide pyrophosphatase/phosphodiesterase 2)	1

主要目的：以武汉人福利康药业有限公司提供的非奈利酮片为受试制剂，按生物等效性试验的有关规定，与Bayer AG公司持证的非奈利酮片（商品名：可申达®，参比制剂）对比在健康试验参与者体内的吸收速度及吸收程度，考察两制剂的人体生物等效性。次要目的：观察非奈利酮片受试制剂和参比制剂（可申达®）在健康试验参与者中的安全性。

[Translation]

Primary objective: To investigate the bioequivalence of fenelazol tablets (provided by Wuhan Renfulikang Pharmaceutical Co., Ltd.) in healthy trial participants, comparing their absorption rate and extent with that of fenelazol tablets (trade name: Keshenda®, reference formulation) certified by Bayer AG, in accordance with relevant bioequivalence testing regulations. Secondary objective: To observe the safety of the fenelazol tablet test formulation and the reference formulation (Keshenda®) in healthy trial participants.

Start Date10 Apr 2026

Sponsor / Collaborator

Wuhan Renfulikang Pharmaceutical Co., Ltd.

CTR20253446

/ RecruitingPhase 3

评价甲苯磺酸卢美哌隆胶囊治疗精神分裂症的有效性和安全性的多中心、随机、双盲双模拟、平行、阳性对照的III期临床试验

[Translation] A multicenter, randomized, double-blind, double-dummy, parallel, positive-controlled phase III clinical trial to evaluate the efficacy and safety of lumepirone tosylate capsules in the treatment of schizophrenia

评价甲苯磺酸卢美哌隆胶囊治疗成人精神分裂症的有效性和安全性

[Translation]

To evaluate the efficacy and safety of lumepirone tosylate capsules in the treatment of schizophrenia in adults

Start Date28 Oct 2025

Sponsor / Collaborator

Wuhan Renfulikang Pharmaceutical Co., Ltd.

[+1]

CTR20251045

/ RecruitingPhase 3

评价盐酸卡利拉嗪胶囊在精神分裂症成人患者中有效性和安全性的随机、双盲双模拟、阳性药物平行对照的多中心Ⅲ期临床试验

[Translation] A randomized, double-blind, double-dummy, positive drug parallel-controlled, multicenter phase III clinical trial to evaluate the efficacy and safety of cariprazine hydrochloride capsules in adult patients with schizophrenia

主要目的：评价盐酸卡利拉嗪胶囊相对于阿立哌唑片在精神分裂症成人患者中的疗效。次要目的：评价盐酸卡利拉嗪胶囊相对于阿立哌唑片在精神分裂症成人患者中的安全性和耐受性。探索性目的：探索受试者对于治疗体验的主观感受。

[Translation]

Primary objective: To evaluate the efficacy of cariprazine hydrochloride capsules compared with aripiprazole tablets in adult patients with schizophrenia. Secondary objective: To evaluate the safety and tolerability of cariprazine hydrochloride capsules compared with aripiprazole tablets in adult patients with schizophrenia. Exploratory objective: To explore the subjective feelings of the subjects about the treatment experience.

Start Date11 Aug 2025

Sponsor / Collaborator

Wuhan Humanwell Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Wuhan Renfulikang Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Wuhan Renfulikang Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Wuhan Renfulikang Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Wuhan Renfulikang Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Phase 2

Login to view more data